Vertex, NHS England no closer to Orkambi settlement
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement...
Orkambi’s Components Trigger Liver Enzyme That Decreases Its Ability to Fight CF, Study Finds
The two components of Orkambi act separately to trigger a liver enzyme that decreases the therapy’s ability to fight cystic fibrosis, a...
GeneFo Releases Updated 2018 Guide to Help Cystic Fibrosis Patients Navigate Treatment Options
GeneFo has put together an updated 2018 guide on treatment options for people with cystic fibrosis (CF) after recent developments again...
New Combination Therapy for Cystic Fibrosis
A new combination of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, tezacaftor and ivacaftor, proved effective...
Introduction of New Therapies Affects Pregnancy Rates in Women With CF, Study Reports
The overall rate at which women with cystic fibrosis are becoming pregnant dropped slightly in recent years — coinciding with the...
GLPG2222 Plus Kalydeco Shows Positive Clinical Results in Phase 2 Trial, Galapagos Reports
Adding investigational CFTR corrector GLPG2222 safely improved disease parameters in cystic fibrosis (CF) patients treated with Kalydeco...
